Benjamin Derman

Assistant Professor

University of Chicago

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Benjamin Derman is an Assistant Professor at the University of Chicago, specializing in multiple myeloma research. His recent articles focus on innovative therapies, including CAR T-cell therapy and the role of immunotherapy in the treatment of hematologic malignancies. He is particularly interested in real-world evidence and the prognostic implications of minimal residual disease in patients undergoing various treatment regimens.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Tadeusz Kubicki

POLAND

View details

ROBERTO MINA

Assistant professor

ITALY

View details

Saad Usmani

Chief Attending

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Larry Anderson

Professor

University of Texas Southwestern Medical Center

UNITED STATES

View details

Brian Chiu

University of Chicago

UNITED STATES

View details

Wei Zhang

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES

View details

Adam Cohen

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Benjamin Derman

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Current and future role of carfilzomib‐based quadruplet combinations as therapy for newly diagnosed multiple myeloma

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.

Real-World Evidence Evaluating Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Systematic Literature Review

Brain-to-vein and vein-to-vein times and outcomes in CAR T-cell therapy in myeloma

Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias

Distinguishing Daratumumab from Endogenous Monoclonal Proteins in Serum from Multiple Myeloma Patients Using an Automated Mass Spectrometry System

Evolution of clonal hematopoiesis on and off lenalidomide maintenance for multiple myeloma

Germline predisposition in multiple myeloma

Intrathecal chemotherapy for ciltacabtagene autoleucel–associated movement and neurocognitive toxicity

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma

Clinician attitudes and practices toward measurable residual disease in multiple myeloma

Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia

Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: Pilot study

Collaborators (7)

Tadeusz Kubicki

ROBERTO MINA

Saad Usmani

Larry Anderson

Brian Chiu

Wei Zhang

Adam Cohen

Make your next move.